Effect of product on pimple spots
- Conditions
- Health Condition 1: L819- Disorder of pigmentation, unspecified
- Registration Number
- CTRI/2024/08/072028
- Lead Sponsor
- Onesto Labs Pvt. Ltd.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
1.Indian female subjects.
2.Healthy subjects
3.Skin is healthy on the studied anatomic unit (free of eczema, wounds, inflammatory scar….).
4.Having hyperpigmentation (Acne PIH) dark spot
Being pregnant or breastfeeding or having stopped to breastfeed in the past three months.
• Having refused to give her assent by signing the consent form.
• Taking part in another study liable to interfere with this study.
• Having a chronic dermatosis liable to modify the cutaneous reactivity on the tested area.
• Being insulin-dependent diabetic or non-insulin-dependent diabetic with a recent therapy (less
than 6 months).
• Having a progressive asthma (either under treatment or last fit in the last 2 years).
• Being epileptic.
• Having non stabilized thyroid problems (requirement of a stabilized treatment for at least 6
months).
• Having cutaneous hypersensitivity
• Having a diagnosed or highly probable allergy to one or several compounds of the cosmetic
products or food products or to latex
• Having known allergy to any of the Ingredient of the Test Product.
• Following a chronic medicinal treatment comprising any of the following products: aspirin-based
products, anti-inflammatories, anti-histamines, corticotherapy, taken by general or local routes
(the only medication permitted is paracetamol)
• Having undergone a surgery requiring a general anaesthetic of more than one hour in the past 6
months.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method